Alpine Select AG Stock

Equities

ALPN

CH0019199550

Investment Management & Fund Operators

Market Closed - Swiss Exchange 11:30:51 2024-04-16 am EDT 5-day change 1st Jan Change
7.85 CHF +0.64% Intraday chart for Alpine Select AG +1.95% 0.00%
Sales 2022 1.62M 1.77M Sales 2023 5.72M 6.26M Capitalization 68.37M 74.87M
Net income 2022 -28M -30.66M Net income 2023 - 0 EV / Sales 2022 58.6 x
Net cash position 2022 12.44M 13.62M Net cash position 2023 5.03M 5.51M EV / Sales 2023 11.1 x
P/E ratio 2022
-3.71 x
P/E ratio 2023
-163 x
Employees 3
Yield 2022
8.26%
Yield 2023
-
Free-Float 31.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.64%
1 week+1.95%
Current month+1.95%
1 month-1.88%
3 months+1.95%
6 months+9.03%
More quotes
1 week
7.05
Extreme 7.05
7.85
1 month
7.05
Extreme 7.05
8.00
Current year
7.05
Extreme 7.05
8.00
1 year
6.90
Extreme 6.9
12.10
3 years
6.90
Extreme 6.9
15.70
5 years
6.90
Extreme 6.9
15.70
10 years
6.90
Extreme 6.9
19.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 13-06-30
Chief Operating Officer - 18-04-30
Chief Investment Officer 66 17-05-21
Members of the board TitleAgeSince
Chairman 64 13-04-24
Director/Board Member 62 11-12-31
Chief Investment Officer 66 17-05-21
More insiders
Date Price Change Volume
24-04-16 7.85 +0.64% 1 200
24-04-15 7.8 0.00% 0
24-04-12 7.8 0.00% 16,000
24-04-11 7.8 +0.65% 1,381
24-04-10 7.75 +0.65% 5,125

Delayed Quote Swiss Exchange, April 16, 2024 at 08:32 am EDT

More quotes
Alpine Select AG (Alpine) is a Switzerland-based investment company. The Company's emphasis lies on securities, quoted or otherwise, of Swiss and foreign corporations, which are subject to particular corporate events such as spin-offs, acquisitions, recapitalizations and reorganizations, or circumstances including valuation anomalies or technical market situations. Alpine Select AG’s investment portfolio is primarily comprised of quoted securities. As of December 31, 2011, the Company’s investments included Absolute Invest AG, Absolute Private Equity AG, AIRE GmbH & Co KGaA, Atrium V Ltd, BB Biotech AG and HBM Bioventures AG, among others. The Company operates through its wholly owned subsidiary, Sumara AG.
More about the company